Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
CANCER:
Ependymoma
Associations
(8)
News
Trials
A1 | Sensitive
A2 | Sensitive
D | Sensitive
A1 | Resistant
A2 | Resistant
D | Resistant
Show legend
Group by Gene:
Include preclinical:
Drug categories
Chemotherapy
DNA
EGFR
Tyrosine Kinase Inhibitors
Cyclin Dependent Kinase Inhibitors
Serine-Threonine Kinase Inhibitors
CD Protein Inhibitors
Cancel
DNA synthesis inhibitor
temozolomide
VEGF-A inhibitor
bevacizumab
Topoisomerase II inhibitor
etoposide IV
Alkylating agent
lomustine
Alkylating agent, DNA synthesis inhibitor
carmustine
HER2 inhibitor, EGFR inhibitor
lapatinib
CDK4 inhibitor, CDK6 inhibitor
abemaciclib
No biomarker
A2
No biomarker
|
Ependymoma
|
temozolomide
A2
No biomarker
|
Ependymoma
|
bevacizumab
A2
No biomarker
|
Ependymoma
|
etoposide IV
A2
No biomarker
|
Ependymoma
|
lomustine
A1
No biomarker
|
Ependymoma
|
carmustine
A2
No biomarker
|
Ependymoma
|
lapatinib
CDK4 overexpression
D
CDK4 overexpression
|
Ependymoma
|
abemaciclib
CCND1 overexpression
D
CCND1 overexpression
|
Ependymoma
|
abemaciclib
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
